Gabapentin Tablet
Product Images NDC 71335-2048

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2048). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

A formula displaying the calculation for creatinine clearance (CLCr) that accounts for age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with scores decreasing for Gabapentin while remaining relatively stable for placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain score over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The chart includes a 3-week dose titration period followed by a 4-week fixed dose period, illustrating decreasing pain scores with both Gabapentin doses compared to placebo.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' showing results from two studies. Study 1 compares placebo (12% responders) and gabapentin 3600 mg (29% responders). Study 2 compares placebo (14%), gabapentin 1800 mg (32%), and gabapentin 2400 mg (34%) responders. Statistical significance markers are noted with p-values < 0.01 and < 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot showing the percentage difference versus daily dose (mg) of a drug across three studies labeled 'a,' 'b,' and 'c.' The x-axis represents daily dose in milligrams (600 to 1800 mg), and the y-axis shows percentage difference (2% to 22%). Data points are marked with different shapes and colors corresponding to each study.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of Gabapentin, depicting its cyclohexane ring with attached amino (CH2NH2) and carboxymethyl (CH2CO2H) functional groups.*

FDA Label Image

Label (Lbl713352048)

Gabapentin 600 mg tablet packaging label from Bryant Ranch Prepack. The label includes a comparison to Neurontin 600 mg tablets by Alkem Laboratories, states the package contains 90 tablets, and lists storage instructions at 20°-25°C (68°-77°F). It includes a warning to keep all drugs out of reach of children and mentions that the product may cause dizziness. The NDC number 71335-2048-1 is visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.